In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF(165) neutralization

The stability, binding, and tissue penetration of variable new-antigen receptor (VNAR) single-domain antibodies have been tested as part of an investigation into their ability to serve as novel therapeutics. V13 is a VNAR that recognizes vascular endothelial growth factor 165 (VEGF(165)). In the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Millán-Gómez, Dalia, Dueñas, Salvador, Muñoz, Patricia L. A., Camacho-Villegas, Tanya, Elosua, Carolina, Cabanillas-Bernal, Olivia, Escalante, Teresa, Perona, Almudena, Abia, David, Drescher, Florian, Fournier, Pierrick G. J., Ramos, Marco A., Mares, Rosa E., Paniagua-Solis, Jorge, Mata-Gonzalez, Teresa, Gonzalez-Canudas, Jorge, Hoffman, Robert M., Licea-Navarro, Alexei, Sánchez-Campos, Noemí
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021326/
https://www.ncbi.nlm.nih.gov/pubmed/29963259
http://dx.doi.org/10.18632/oncotarget.25549

Ejemplares similares

Ejemplares similares